StandardX, a new UK company, has launched with a £10 million seed round to make the rare isotopes that cancer medicine and fusion energy both depend on. Vsquared Ventures and East X Ventures led the round. firstminute capital, the UK Innovation and Science Seed Fund, Brevan Howard Macro Venture and Geometry also invested.
Isotopes rarely make headlines, but plenty of modern medicine runs on them. They light up tumors in diagnostic scans. Newer targeted alpha therapies carry radiation straight to cancer cells. Fusion reactors need tritium for fuel. Yet global production is, in StandardX’s words, “constrained, fragile and fragmented.” It relies on a small number of aging research reactors and single-purpose facilities, each built to make one isotope.
One machine, many isotopes
StandardX wants to replace that model with a proprietary accelerator-based system. It fits on a standard industrial footprint and can make a whole portfolio of isotopes at commercial scale. The first industrial site will be in London. The company plans to supply its first isotopes to a medical research partner in 2027 and to reach industrial-scale production in 2029.
The shortage is already costing patients. Clinical trials of advanced cancer treatments have been paused because isotopes weren’t available. In May 2026 the NHS met its cancer waiting-time standard for just 69.6% of patients, against an 85% target.
The team
CEO Richard Pearson and CTO Ross Allen are both nuclear engineers with experience scaling startups. “Isotopes underpin the next era of innovation across several key sectors,” Pearson says. “So we’re building the platform the world needs.”
For fusion developers, a steady tritium supply is a hard limit on how fast pilot plants can run. For oncologists, reliable isotopes decide whether new therapies reach patients at all. StandardX is betting one platform can serve both.